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Background: In ductal carcinoma in situ of the breast (DCIS), histologic diagnosis obtained before the definitive
treatment is related to the risk of underestimation if the presence of invasive cancer is found postoperatively. These
patients need a second operation to assess the nodal status. We evaluated the upstaging rate in patients with
mass-forming DCIS.
Methods: Sixty-three women with pure DCIS presenting as sonographic mass lesion underwent vacuum-assisted
or core-needle biopsy and subsequent surgery. Rates of postoperative upstaging to invasive cancer were calculated
and compared with clinical character and size of DCIS.
Results: Median age of patients (range) was 63 years (27–88) while median diameter of DCIS was 11 mm (6–60).
Fifty-six percent of DCIS were upstaged. Patient age did not differ significantly between groups with and without
final invasion (median, mean, SD): 63, 61.4, 12.5 vs 62, 61.2, 10.6 years, respectively (P = 0.659). The difference of
DCIS size between these groups was statistically important (median, mean, SD): 13, 17.3, 11.4 vs 9.5, 9.8, 3.2 mm,
respectively (P = 0.0003). Mass size and palpability were significant risk factors (P < 0.001 and P < 0.01, respectively).
Rate of underestimation for mass with diameter ≤10 mm, 10–20 mm and >20 mm was 37, 64 and 91 %, respectively.
Conclusions: DCIS diagnosed on minimal-invasive biopsy of even small sonographic mass is of high risk for the
upstaging to invasive cancer after final surgical excision. In these patients, subsequent intervention is needed for
nodal status assessment. They are good candidates for the sentinel node biopsy during the breast operation to
avoid multi-step surgery.
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The widespread uptake of contemporary breast imaging
modalities have resulted in an increase in diagnosis of
borderline lesions and preinvasive cancers including
ductal carcinoma in situ (DCIS), which is usually pre-
senting on mammography as microcalcifications [1]. The
overall natural progression of DCIS to invasive malig-
nancy is reported to range from 14 to 75 %, which re-
flects their variable malignant potential and biological* Correspondence: szynglarewicz.b@dco.com.pl
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creativecommons.org/publicdomain/zero/1.0/diversity [2]. Histopathologic diagnosis of breast cancer
should be obtained before the definitive treatment using
minimal-invasive investigations. However, it is related to
the risk of the presence of invasive ductal cancer (IDC)
that can be found in postoperative specimen after surgical
excision. These patients need subsequent re-operation—
usually a sentinel node biopsy to assess the nodal status [3].
Some features of DCIS with more aggressive biology have
been identified (high nuclear grade, comedonecrosis), some
remain disputable and many others are a matter of in-
vestigation [4]. Moreover, not all the variables helpful for
optimal treatment planning are available before the final
examination of postoperative specimen (e.g. microscopicccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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Nuys Prognostic Index).
Among radiological features, the mammographic ex-
tent over than 4–5 cm and the presence of architectural
distortion, focal asymmetric density or mass on mam-
mography are proven important risk factors of histo-
logical underestimation [5, 6]. In addition, in some
reports, a mass lesion visible on ultrasound can be sig-
nificantly related to the risk of upstaging DCIS to IDC
[6]. The cut-off point of lesion size that makes a distinc-
tion between low- and high-risk DCIS is still a subject of
debate. However, it tends to decrease. Based on recent
findings, the significant cut-off point seems to be much
smaller than traditional [7].
The primary aim of this study was to assess the post-
operative upstaging rate in patients with mass-forming
pure DCIS with histologic diagnosis obtained from pre-
operative, image-guided breast biopsy. The secondary
aim was to evaluate its relation to the lesion size, par-
ticularly with regard to small, non-palpable DCIS.
Methods
Patients
During the years 2004–2014 in our institution, 8403
percutaneous biopsies of suspicious breast masses under
ultrasound guidance (vacuum assisted or core needle with
automated gun) were performed. In histological examin-
ation of biopsy specimens, DCIS was found as a part of
targeted mass in 91 patients. Of them, three had breast
cancer history: IDC of contralateral breast, DCIS of
contralateral breast (diagnosed on stereotactic biopsy
of microcalcifications without mass) and IDC of ipsilat-
eral breast (other quadrant), respectively. In every case,
mammography and ultrasound were done. Two lesions
were presenting as solid mass without any other mam-
mographic manifestation. Mammography demonstrated
mass with architectural distortion and mass with focal
asymmetric density in three and two patients, respectively.
In the remaining cases, DCIS was detected in mammog-
raphy as a mass with associated microcalcifications, with
the highest percentage being crushed stone type, the
second-most common linear casting type and the less fre-
quent powderish type. Nevertheless, because the lesions
were sonographically visible as evident mass (most com-
mon microlobulated, hypoechoic), patients were referred
to ultrasound-guided biopsy as the preferable option in
our institution in cases of tumours detectable both in
mammography and sonography. This management is
based on the fact that biopsy under ultrasound guidance
has some advantages: it is performed in a real time, direct
needle visualization allows accuracy of sampling to be
assessed, does not involve ionizing radiation, its sensitivity
is higher, procedure is faster and more comfortable for a
patient [8–11].Pathologic assessment
All haematoxylin-and-eosin-stained slides of formalin-
fixed and paraffin-embedded tissue blocks were assessed
by board-certified pathologists experienced in breast
cancer. In 26 cases, invasion or microinvasion (≤1 mm
in the longest diameter) was found—these patients were
excluded from the analysis. Then, the subsequent surgi-
cal excision was completed. Two women had surgery in
other institutions and data from follow-up excision were
not available. In the remaining cases, postoperative
pathologic examination was performed. Special effort
was made to find any foci of IDC in the surgical speci-
men. All the biopsy and excision slides were reviewed
and re-evaluated by study supervising pathologist (AH)
to confirm the original diagnosis of DCIS, as well as the
absence or presence of invasion or microinvasion. Fi-
nally, 63 patients entered the study fulfilling the inclusion
criteria: sonographic mass lesion, BIRADS category 4 or 5,
ultrasound-guided core needle or vacuum-assisted biopsy,
pure DCIS in histologic assessment of biopsy specimens,
material of surgical excision available for postoperative
pathologic examination.
Minimally invasive ultrasound-guided biopsy
Ultrasound-guided biopsies were performed with the pa-
tients in the supine or supine-oblique position in a
breast sonography unit. Biopsies were carried out strictly
according to standardized protocol of this procedure by
one breast-dedicated radiologist (PK), after reading
mammograms and performing diagnostic sonography to
individually tailor the biopsy technique. Clinical character
of lesion (palpable vs non-palpable) was also examined by
the same radiologist. In cases of palpable tumour (29/63),
core-needle biopsy with 14-G needle using automated gun
was done (Manan Pro-MagTM 2.2, Angiotech Pharmaceuti-
cals Inc, distributed in Europe by PBN Medicals, Stenlose,
Denmark). For non-palpable lesions (34/63), vacuum-
assisted biopsy was performed with 11-G needle (Mammo-
tome System MHH 11, Ethicon EndoSurgery Europe,
Norderstedt, Germany) or 10-G needle (EnCore Breast
Biopsy System, SenoRx Inc., Irvine, CA or EnCore Enspire
Breast Biopsy System, C.R. Bard Inc., Tempe, AZ, USA).
Surgical excision
The subsequent surgical excision was carried out in all
analysed cases. For each patient, both tumour and all
planned incisions were marked on the skin before surgery.
Preoperative skin markings were done with the patient in
the upright position. In non-palpable tumours, needle
localisation of the lesion was made under the local anaes-
thesia. Needle localisation was performed using Accura
BLN device (MDTech, Gainesville, FL, USA; distribution
in Europe by PBN Medicals, Stenlose, Denmark) through
the post-biopsy scar. After the needle was placed and its
Table 1 Rate of upstaging to invasive ductal cancer after
subsequent surgical excision
DCIS presenting as a mass Rate of upstaging P value
All mass DCIS 56 % (35/63) -
Palpability Absent 38 % (13/34) <0.01
Present 76 % (22/29)
Size ≤10 mm 37 % (11/30) <0.01
>10 mm 73 % (24/33)
≤15 mm 43 % (20/47) <0.001
>15 mm 94 % (15/16)
≤20 mm 48 % (25/52) >0.05
>20 mm 91 % (10/11)
≤30 mm 52 % (30/58) <0.05
>30 mm 100 % (5/5)
Szynglarewicz et al. World Journal of Surgical Oncology  (2015) 13:218 Page 3 of 4position was confirmed, the hook wire was deployed and
the ultrasound view was obtained to confirm wire pos-
ition. In all the cases, postoperative tissue specimen was
oriented in three dimensions by the surgeon and inked to
assist in identifying margins.
Statistical analysis
Data were collected in a prospective manner and then
were entered into computer database. In each case, pa-
tient age, history of breast cancer, radiological presenta-
tion, pathologic findings, clinical character and mass size
(the longest diameter in ultrasound examination) were
measured. Mean, standard deviation, median and range
values were calculated when appropriate. Rates of up-
staging to IDC were calculated and compared to clinical
character and size of DCIS. Continuous variables were
compared between two groups using Mann–Whitney U-
test. Categorical variables were analysed using Pearson’s
chi-square test. P values less than 0.05 were considered
statistically significant.
Results
Median age of patients (mean, SD, range) was 63 years
(61.3, 11.5, 27–88). Median diameter of DCIS was 11 mm
(13.9, 9.4, 6–60). Foci of IDC were found in postoperative
specimen in 56 % of DCIS presenting as a sonographic
mass (35/63). Patient age did not differ significantly be-
tween groups with and without final IDC (median, mean,
SD): 63, 61.4, 12.5 vs 62, 61.2, 10.6 years, respectively
(P = 0.659). The difference of DCIS size between these
groups was statistically important (median, mean, SD): 13,
17.3, 11.4 vs 9.5, 9.8, 3.2 mm, respectively (P = 0.0003).
Palpable lesions were significantly more often upstaged to
invasive cancer: 76 vs 38 % (P = 0.0027). Rates of under-
estimation were associated with the size of DCIS: 91 %
(10/11) for greater than 20 mm, 64 % (14/22) for 10–
20 mm and 37 % (11/30) for equal or smaller than
10 mm. Association between the risk of upstaging to inva-
sive disease and clinical character as well as diameter of
DCIS using different cut-off points (10, 15, 20 and 30 mm;
P = 0.0040, 0.0003, 0.9717 and 0.0371, respectively) is pre-
sented in Table 1.
Discussion
Based on the final pathology, we found the upstaging of
DCIS to IDC in 56 % of patients, which is higher than
18–43 % reported in current literature [6, 12–16]. Rate
of upstaging depends on the biopsy method (core-needle vs
vacuum-assisted) [12–15] as well as radiological guidance
(ultrasound-guided vs stereotactic) and average tumour size
[16]. High rate in our group, despite minimum five tissue
cores and the use of vacuum-assisted technique (high-vol-
ume specimens) in non-palpable DCIS, cannot be simply
explained by these factors.It is rather due to the fact that all investigated DCIS
was presenting as a mass on mammography, which is re-
lated to important risk of upstaging [14, 16]. Moreover,
some studies report that sonographic mass (as in our
study) can be a significant [6] and independent [13] pre-
dictor of invasion. This kind of radiological presentation
can reflect higher potential of local invasiveness: break-
ing through the basement membrane of the breast duct
and infiltration of deeper tissues. It is still a subject of
debate if the clinical character of mass (palpable vs
non-palpable) plays an important role: some data are
against [12], some are for [15]. Current multivariate
analyses revealed statistically significant association between
palpability of DCIS and the risk of invasion (46–70 % vs
23–30 %) [13, 14]. In a series of Schulz and colleagues, it
was the essential and only independent factor [6]. Never-
theless, in the absence of properly randomized studies, the
true correlation remains unclear and significant and signifi-
cant conclusions cannot be drawn.
Traditionally, DCIS with the extent over 4–5 cm has
been considered a high-risk lesion for upstaging to inva-
sive cancer [5]. These patients should undergo an axil-
lary nodal staging with sentinel node biopsy. However,
during the few last years, the recommended cut-off point
much decreased in size, to 25 mm [7]. Some recent
studies report 20 mm as a significant value [14, 15, 17].
Lee and colleagues and Park and co-investigators suggest
even smaller cut-off point: 15 mm (34.6 vs 0.4 %) and
10 mm (60.3 vs 39.7 %), respectively [12, 13]. Data from
this last report are in concordance with our findings that
in some clinical subtypes of DCIS with specific and less
common radiographic manifestation as a mass, the risk
of upstaging to IDC after subsequent surgical excision is
remarkably high even when the lesion is very small.
Our study has some limitations. First, this is a single
centre series—our findings may not be applicable to spe-
cific patient cohort managed in other institution. Second,
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the ability to prove statistical significance. Third, a variety
of minimally invasive biopsy techniques (vacuum assisted
and core needle with automated gun) and needle gauges
were used. The use of one biopsy technique with one
needle gauge would be ideal for the confidence of re-
sults. Despite these important limitations, our findings
are potentially interesting from a clinical point of view.
Conclusions
Considerable risk of DCIS upstaging in patients with
even small lesions presenting as a mass can be helpful
for optimal treatment planning. It should be taken into
account in decision-making process with regard to the
extent of surgical intervention.
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